Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase
| Autor: | Mirta Grifman, Guohong Liu, Flossie Wong-Staal, Peter Möller, Qi-Xiang Li, James W. MacDonald |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Endocrinology Diabetes and Metabolism Blotting Western Enzyme-Linked Immunosorbent Assay AMP-Activated Protein Kinases Protein Serine-Threonine Kinases Biology Rosiglitazone Mice Endocrinology AMP-activated protein kinase Multienzyme Complexes 3T3-L1 Cells Internal medicine Adipocytes medicine Animals Biflavonoids Hypoglycemic Agents Adiponectin secretion Thiazolidinedione Protein kinase A Flavonoids Adipogenesis Adiponectin Reverse Transcriptase Polymerase Chain Reaction AMPK Up-Regulation PPAR gamma biology.protein Thiazolidinediones hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Journal of Endocrinology. 194:569-578 |
| ISSN: | 1479-6805 0022-0795 |
| DOI: | 10.1677/joe-07-0200 |
| Popis: | Adiponectin is an anti-diabetic hormone secreted byadipocytes. Circulating adiponectin levels are lower in obese and type II diabetic patients than in healthy people. Weight loss or thiazolidinedione treatment increases plasma adiponectin levels. Animal models and human studies suggest that elevated adiponectin levels increase insulin sensitivity. We screened a library of drug-like compounds and natural products for novel agents enhancing adiponectin production. We identified isoginkgetin, a compound derived from the leaves of Ginkgo biloba, to up-regulate adiponectin secretion with potency comparable to that of rosiglitazone, a known modulator of adiponectin production. However, unlike rosiglitazone, peroxisome proliferators-activated receptor γ activity seems not required for the action of isoginkgetin, and isoginkgetin has only a slight effect on adipogenesis, which makes it an attractive candidate for anti-diabetic treatment. Further investigation revealed that both isoginkgetin and rosiglitazone activate AMP-activated protein kinase (AMPK) in adipocytes. Our findings suggest a novel mechanism for the elevation of adiponectin by isoginkgetin, which is different from that of rosiglitazone. Furthermore, this novel mechanism for adiponectin regulation involving AMPK can potentially facilitate new understanding of metabolic diseases and identification of new targets, as well as agents that increase plasma adiponectin levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|